26 July 2021
NovaMedica, a Russian pharmaceutical company and portfolio project of the national nanotech company Rusnano, has developed what might emerge into a market-winning new drug for colorectal therapy.
The new Russian drug offers in itself a combination of two active ingredients with therapeutic and pain-relieving effects. In its R&D process, NovaMedica is said to have applied technologies enabling such a combination in one product, bringing together substances that were once considered incompatible and exponentially improving their physical-chemical properties as a result.
Last month the German chemical-pharmaceutical giant Bayer inked an agreement with NovaMedica which gave the Germans an exclusive license for the commercialization of the drug. The German firm obtained the rights to both manufacture the drug and market it.
Bayer is reportedly going to bring the innovative medicine to market under the Reliefipin brand name.
14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
Big Pharma’s ROI for drug R&D saw 'welcome' rebound in 2023: report
25 April 2024
Orphan drug market to reach $270B by 2028 : Evaluate
25 April 2024
Russian drug for the treatment of viral hepatitis will be exempt from duty in Mongolia
24 April 2024
PM Mishustin: “We need to increase the production of vital and essential drugs in Russia”
24 April 2024